Couldn't agree more biotechasx. A friend of mine emailed the company last week to enquire about the regulatory pathway for their secretions technology. This was the response
"Thanks for your email. There are a couple of options to follow in regards to the secretions technology - the therapeutics and the cosmetics. We are currently exploring both.
The therapeutics route would follow a regulatory pathway and clinical trials would need to be conducted for each indication you wanted to follow.
Our strategy with all of our technology platforms, including secretions is to do a number of pilot / pre-clinical studies in various areas to get some indication usually via non-controlled data, to decide if we would pursue a certain indication. Any further development would be through licensing with partners who wanted to pursue a certain indication, generally pharmaceutical companies and who would pay a licence fee to access the technology and they would be responsible for any costs in further trials.
The cosmetic pathway would be a lot faster and doesn't have as much regulation surrounding it.
We continue to have discussions with parties for the development and commercialisation opportunities for the secretions technology in both the therapeutic and cosmetic markets. "
Pretty exciting times for this company I think. Just ticking all the right boxes. Amazing to only have a market cap of $30M odd. Getting into Asian markets is such a good move.
RGS Price at posting:
15.0¢ Sentiment: Buy Disclosure: Held
